Company news

Ultragenyx Pharmaceutical Inc. news in 2026

Ultragenyx Pharmaceutical Inc.'s news releases, calls and decks from 2026, newest first.

View company

Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update

October 27, 2026

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million

October 14, 2026

Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million

October 7, 2026

Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A)

October 2, 2026

Ultragenyx Announces Approval of FAYUVI Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A

September 18, 2026

Ultragenyx Announces Approval of FAYUVI™ Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA)

September 17, 2026

Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome

September 2, 2026

Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS™ (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease

September 1, 2026

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

August 20, 2026

Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)

August 19, 2026

Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update

August 4, 2026

Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update

July 28, 2026

Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact

July 8, 2026

Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference

June 3, 2026

Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference

May 6, 2026

Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update

May 5, 2026

Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update

April 29, 2026

Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)

April 1, 2026

Ultragenyx Announces FDA Clearance of Investigational New Drug Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

March 31, 2026

Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy

March 29, 2026

Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency

March 11, 2026

Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)

February 23, 2026

Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update

February 12, 2026

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update

February 5, 2026

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA)

February 3, 2026

Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in C...

February 2, 2026

Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA

January 30, 2026

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

January 23, 2026

Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference

January 12, 2026

Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference

January 7, 2026

Calls in 2026

Decks in 2026